AUS
NZ
UK
CA
USA
IND
Ansell Ltd (ASX: ANN) shares re-emerged from a trading halt on Tuesday with a remarkable 5.88% surge, reaching AU$25.30 in afternoon trade (at 2:34PM AEST).
Investor enthusiasm was ignited by a major announcement from the company. Ansell successfully concluded a fully underwritten institutional placement, raising approximately AU$400 million (US$2631 million) through the issuance of around 17.8 million new fully paid ordinary shares to eligible institutional investors. The placement was executed at a price of AU$22.45 per new share, reflecting a 6% discount compared to the last traded price of Ansell shares.
Ansell reported robust interest from both existing and new institutional investors in the placement. Following this, the company is now set to proceed with its share purchase plan (SPP), aiming to raise an additional $65 million. The SPP will be priced at either the placement price or a 2% discount to the five-day volume weighted average price of Ansell shares up to the closing date, scheduled for 6 May 2024.
The primary motive behind this fundraising initiative is Ansell's blockbuster acquisition plans. Recently, the company entered into a binding agreement with Kimberly-Clark Corp (NYSE:KMB) to acquire 100% of the assets of its Personal Protective Equipment (PPE) business. Kimberly-Clark, renowned for consumer staples like Huggies and Kleenex, holds a significant presence in the PPE sector.
Ansell is set to acquire this business for US$640 million (AU$970 million) in cash, encompassing well-known brands such as Kimtech and KleenGuard, alongside glove, mask, apparel, and eyewear manufacturing facilities. Management views this acquisition as a strategic move to expedite its growth strategy and enhance its global position in burgeoning market segments. Moreover, it anticipates deriving economies of scale through synergies in supply chain and organizational efficiency.
The financial outlook accompanying the acquisition has also bolstered investor confidence. Management anticipates mid-to-high single-digit earnings per share accretion pre-synergies and low-teens earnings per share accretion, including run-rate net cost synergies on a FY 2024 pro forma basis.
Neil Salmon, Ansell's managing director and CEO, expressed his satisfaction with the agreement, emphasizing the long-standing appeal of this acquisition opportunity. He highlighted the acquisition's potential to bolster sales of specialist products and broaden Ansell's product portfolio, particularly in scientific verticals such as pharmaceuticals, medical devices, and semiconductor manufacturing.
In summary, Ansell's strategic acquisition and successful fundraising initiatives mark significant milestones in the company's growth trajectory, positioning it favorably for future expansion and value creation in the health and safety products market.
